Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05342519Phase 2Active Not Recruiting

Daily Topical Rapamycin for Vitiligo

Role: collaborator

NCT03180528Phase 2Completed

Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

Role: collaborator

NCT00177034Not ApplicableTerminated

Examination Of Vitiligo Skin Samples Before and After UVB Treatment

Role: collaborator

All 3 trials loaded